Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$805.58 USD

805.58
3,020,013

-13.35 (-1.63%)

Updated Nov 4, 2024 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus

by Zacks Equity Research

The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.

    Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year

    by Zacks Equity Research

    ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.

      FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy

      by Zacks Equity Research

      Bristol-Myers' (BMY) filing for Opdivo in combination with Yervoy gains acceptance from the FDA for treating metastatic colorectal cancer. A response is expected in July, 2018.

        The Zacks Analyst Blog Highlights: Nike, Eli Lilly, NVIDIA, L Brands and Alleghany

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Nike, Eli Lilly, NVIDIA, L Brands and Alleghany

          Roche's Tecentriq Combo Study Meets Co-Primary Endpoint

          by Zacks Equity Research

          Roche's (RHHBY) phase III study, evaluating a combination of Tecentriq and Avastin plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co-primary endpoint of overall survival.

            Pfizer's Chantix Fails in Phase IV Study in Young Smokers

            by Zacks Equity Research

            Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.

              Radius Health Down on Negative CHMP Opinion for Lead Drug

              by Zacks Equity Research

              Shares of Radius Health (RDUS) declined after the company's application for lead drug, abaloparatide-SC, was given a negative opinion by the CHMP in Europe.

                Merck Gets European Committee Vote for Veterinary Product

                by Zacks Equity Research

                Merck (MRK) is seeking approval of Bravecto Plus, a spot-on solution for cats. The drug is part of the company's Animal Health unit.

                  Swarup Gupta headshot

                  Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks

                  by Swarup Gupta

                  Industry watchers have grown skeptical about Trump's intermittent pronouncements on this issue.

                    Roche Tecentriq Phase III Combo Study Meets Primary Endpoint

                    by Zacks Equity Research

                    Roche (RHHBY) announces that the combination study of Tecentriq plus chemotherapy meets its co-primary endpoint of progression-free survival.

                      Radius Health Announces Positive Data on Lead Drug Tymlos

                      by Zacks Equity Research

                      Radius Health (RDUS) announces positive results from the extended study, ACTIVExtend on its drug Tymlos whcih is approved for the treatment of postmenopausal women with high risk osteoporosis for fracture.

                        Is Eli Lilly and Company (LLY) Stock a Good Value Pick Now?

                        by Zacks Equity Research

                        Let's see if Eli Lilly and Company (LLY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                          AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down

                          by Zacks Equity Research

                          AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.

                            Merck's Keytruda Gets Priority Review for Cervical Cancer

                            by Zacks Equity Research

                            Merck's (MRK) sBLA for Keytruda to expand its label for the treatment of advanced cervical cancer gets acceptance for priority review by the FDA.

                              The Zacks Analyst Blog Highlights: Coca-Cola, Eli Lilly, Occidental Petroleum, Ross Stores and Wynn Resorts

                              by Zacks Equity Research

                              The Zacks Analyst Blog Highlights: Coca-Cola, Eli Lilly, Occidental Petroleum, Ross Stores and Wynn Resorts

                                Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up

                                by Zacks Equity Research

                                Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.

                                  Merck to Pay $300M Upfront to Co-Develop Eisai's Cancer Drug

                                  by Zacks Equity Research

                                  Merck (MRK) is going to pay $300 million upfront to Japan's Eisai to jointly develop and commercialize the latter's pipeline candidate Lenvima.

                                    Lilly, Boehringer to Expand Jardiance Heart Failure Program

                                    by Zacks Equity Research

                                    Lilly (LLY) and Boehringer plan to expand their clinical trial program for Jardiance in chronic heart failure through clinical trials.

                                      Are Alzheimer's-Focused Stocks Set for a Financial Windfall?

                                      by Zacks Equity Research

                                      Launch of the blood tests will help companies focused on developing preventive treatments make billions.

                                        Radius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses

                                        by Zacks Equity Research

                                        Radius Health (RDUS) reported a wider-than-expected loss in the fourth quarter due to higher operating expenses related to the commercialization of Tymlos.

                                          Why Is Eli Lilly (LLY) Down 7.2% Since its Last Earnings Report?

                                          by Zacks Equity Research

                                          Eli Lilly (LLY) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.

                                            Lilly's Verzenio Wins FDA Nod for First Line Breast Cancer

                                            by Zacks Equity Research

                                            Lilly's (LLY) new advanced breast cancer treatment Verzenio (abemaciclib) gains FDA approval in first-line setting.

                                              Radius Health (RDUS) to Disappoint Investors in Q4 Earnings?

                                              by Zacks Equity Research

                                              Investors are expected to focus on the uptake of the lead drug, Tymlos when Radius Health (RDUS) reports its fourth-quarter results.

                                                United Therapeutics (UTHR) Q4 Earnings Decline on High Costs

                                                by Zacks Equity Research

                                                United Therapeutics' (UTHR) earnings per share decline in Q4 due to higher operating costs. Shares sink almost 10%.

                                                  FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments

                                                  by Zacks Equity Research

                                                  FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.